share_log

UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer

Benzinga Real-time News ·  Sep 20, 2022 06:46
  • England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ:BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.
  • This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales.
  • Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study.
  • WM is a rare form of B-cell lymphoma that occurs in less than two percent of patients with non-Hodgkin lymphomas. Around 4,000 people are living with WM in the U.K.
  • The NICE recommendation states that Brukinsa is considered cost-effective at a threshold of £20,000-30,000 per quality-adjusted life year.
  • Also, the European Medicines Agency's Committee for Medicinal Products for Human Use backed Brukinsa approval for marginal zone lymphoma patients who have received at least one prior anti-CD20-based therapy.
  • Price Action: BGNE shares closed lower by 1.45% at $154.82 on Monday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment